Coherus Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Coherus Oncology, Inc. on January 23, 2026. The filing addresses Item 8.01 (Other Events) regarding the execution of a prospectus supplement for an existing at-the-market equity offering program.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a potential equity offering.
Material Changes and Transaction Details
- Transaction Type: Filing of a prospectus supplement for an existing Sales Agreement.
- Counterparty: TD Securities (USA) LLC ("TD Cowen"), which assumed the role of sales agent following prior amendments to the agreement originally dated November 8, 2022.
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $64,880,054.
- Stock Details: Common Stock, $0.0001 par value per share, trading under the symbol CHRS on The Nasdaq Global Market.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard legal opinion regarding the validity of the stock issuance. The filing incorporates by reference a legal opinion from Latham & Watkins LLP.
Investor Verification Checklist
- Verify the current share price of CHRS to assess the potential dilution impact of the $64.88 million offering capacity.
- Review the original Sales Agreement (dated November 8, 2022) and its amendments to understand the full terms of the at-the-market facility.
- Confirm the Company's current cash position and liquidity needs to determine the likelihood of utilizing this offering capacity in the near term.
- Check for any subsequent filings indicating actual sales of shares under this prospectus supplement.